Frankfurt
09.02.26 | 08:23
0,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.02.2026 | 644 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 23.02.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.02.2026.ISIN NameCA4987222060 KLONDIKE... ► Artikel lesen | |
| LIDDS Aktie jetzt für 0€ handeln | |||||
| 13.02. | LIDDS AB: LIDDS is declared bankrupt - delisting from First North | 318 | GlobeNewswire (Europe) | On 13 February 2026, the Gothenburg District Court decided to file LIDDS AB (publ) in liquidation ("the Company") for bankruptcy.
Mona Jonasson, Layer at law firm NORDIA Göteborg KB, has been appointed... ► Artikel lesen | |
| 13.02. | LIDDS AB - Removal from trading on Nasdaq First North Growth Market | 196 | GlobeNewswire | Today, February 13, 2026, LIDDS AB was declared bankrupt by the Gothenburg District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to... ► Artikel lesen | |
| 09.02. | LIDDS AB: The liquidator intends to file for bankruptcy as the conditions for completing the liquidation are lacking | 152 | GlobeNewswire (Europe) | Gothenburg, 09/02/2026 - LIDDS AB (publ) ("LIDDS" or the "Company"), listed on Nasdaq First North Growth Market, announces today that the liquidator appointed by the Swedish Companies Registration Office... ► Artikel lesen | |
| 09.02. | XFRA 5LD: AUSSETZUNG/SUSPENSION | 258 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIDDS AB 5LD SE0001958612... ► Artikel lesen | |
| 09.02. | Suspension of Trading in LIDDS AB at FNSE | 237 | GlobeNewswire | 2026-02-09T15:59:18Z
Suspension
At Trading Venue FNSE
Due to Other
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent applicable, also decided to
suspend the trading in all other instruments... ► Artikel lesen | |
| 28.01. | LIDDS AB: Announcement from extraordinary general meeting, as well as second control meeting, in LIDDS AB (publ) held on 28 January 2026 | 78 | GlobeNewswire (Europe) | LIDDS AB (publ) (the "Company") has held an extraordinary general meeting, as well as second control meeting, on 28 January 2026. A summary of the resolutions made at the general meeting follows below.... ► Artikel lesen | |
| 09.01. | The observation status for LIDDS AB is updated | 197 | GlobeNewswire | On April 2, 2025, the shares in LIDDS AB (the "Company") were given observation status with reference to the Company's decision to cease further development of the project areas Nanodotax, Nanoimod... ► Artikel lesen | |
| 09.01. | LIDDS AB: LIDDS AB (publ) proposes that the general meeting, as well as the second control meeting, resolve on voluntary liquidation and the delisting of the company's shares | 260 | GlobeNewswire (Europe) | GOTHENBURG, SWEDEN - The Board of Directors of LIDDS AB (publ) ("LIDDS" or the "Company") has today resolved to propose that an extraordinary general meeting, which will also serve as the second control... ► Artikel lesen | |
| 18.12.25 | LIDDS AB: Announcement from extraordinary general meeting in LIDDS AB (publ) held on 18 December 2025 | 150 | GlobeNewswire (Europe) | LIDDS AB (publ) (the "Company") has held an extraordinary general meeting on 18 December 2025. A summary of the resolutions made at the general meeting follows below. All resolutions have been made... ► Artikel lesen | |
| 11.12.25 | The observation status for LIDDS AB is updated | 229 | GlobeNewswire | On April 2, 2025, the shares in LIDDS AB (the "Company") were given observation status with reference to the Company's decision to cease further development of the project areas Nanodotax, Nanoimod... ► Artikel lesen | |
| 10.12.25 | LIDDS AB: LIDDS AB (publ) has decided to terminate the process regarding the reverse acquisition of Proport Invest AB (publ) | 132 | GlobeNewswire (Europe) | The Board of Directors of LIDDS AB (publ) ("LIDDS" or the "Company") has, after completing due diligence, decided to discontinue the ongoing process for the reverse acquisition of Proport Invest AB... ► Artikel lesen | |
| 28.11.25 | The observation status for LIDDS AB is updated | 196 | GlobeNewswire | On April 2, 2025, the shares in LIDDS AB (the "Company") were given observation status with reference to the Company's decision to cease further development of the project areas Nanodotax, Nanoimod... ► Artikel lesen | |
| 27.11.25 | LIDDS AB: LIDDS AB (publ) has entered into an agreement for a reverse takeover of Proport Invest AB (publ) | 191 | GlobeNewswire (Europe) | LIDDS AB (publ) ("LIDDS" or the "Company") announces that the Company has entered into an agreement for a reverse takeover of Proport Invest AB (publ) ("Proport") regarding all shares in Proport (the... ► Artikel lesen | |
| 20.11.25 | LIDDS AB: LIDDS AB (publ) Interim Report January - September 2025 | 119 | GlobeNewswire (Europe) | July - September 2025Net sales amounted to 0 (0) KSEKThe operating result for the period was -876 (-1,061) KSEKThe net result was -891 (-877) KSEK corresponding to earningsper share of -0.01 (-0.01)... ► Artikel lesen | |
| 13.11.25 | LIDDS AB: The board of directors of LIDDS AB intends to propose a reduction of the company's share capital for loss coverage | 152 | GlobeNewswire (Europe) | GOTHENBURG, SWEDEN - The board of directors of LIDDS AB (publ) ("LIDDS" or the "Company") intends to propose that an extraordinary general meeting of the Company resolve on a reduction of the Company's... ► Artikel lesen | |
| 28.08.25 | LIDDS AB: LIDDS AB (publ) Interim Report January - June 2025 | 188 | GlobeNewswire (Europe) | April - June 2025Net sales amounted to 0 (0) KSEKThe operating result for the period was -836 (-2 391) KSEKThe net result was -733 (-2 398) KSEK corresponding to earnings per share of -0,01 (-0.02)... ► Artikel lesen | |
| 28.05.25 | LIDDS AB: LIDDS AB (publ) Interim Report January - March 2025 | 310 | GlobeNewswire (Europe) | First quarter 2025 (the Group)·Net sales amounted to 0 (0) TSEK·The operating result for the period was -1 254 (-1) TSEK·The net result was -1 311 (-5) TSEK corresponding to earnings per share of -0... ► Artikel lesen | |
| 02.04.25 | LIDDS AB receives observation status | 276 | GlobeNewswire | Today, April 2, 2025, LIDDS AB (the "Company") disclosed a press release with information that the Company's board of directors has decided to cease further development of the project areas Nanodotax... ► Artikel lesen | |
| 02.04.25 | LIDDS AB: LIDDS has decided to cease further development | 272 | GlobeNewswire (Europe) | GOTHENBURG, SWEDEN - The Board of Directors of LIDDS AB (publ) has decided to cease further development of the project areas Nanodotax, Nanoimod, and NOV 202.
The LIDDS board concludes after extensive... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,385 | -0,21 % | Aktien Frankfurt Ausblick: Stabilisierung - Unicredit bietet für Commerzbank | FRANKFURT (dpa-AFX) - Der Dax dürfte recht stabil in den elften Handelstag seit Kriegsausbruch im Iran starten. Der X-Dax signalisierte für den deutschen Leitindex rund eine Stunde vor Handelsbeginn... ► Artikel lesen | |
| MERCK KGAA | 104,05 | -3,07 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 150 Euro auf "Overweight" belassen. Nach den Quartalszahlen des Pharma- und Spezialchemiekonzerns... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,800 | -2,17 % | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| NOVO NORDISK | 31,560 | 0,00 % | HV-Termine: Hauptversammlungen bei All for One, BB Biotech, MeVis, Novo Nordisk, Sartorius | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| PFIZER | 23,315 | +0,15 % | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfizer | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfize ► Artikel lesen | |
| SANOFI | 76,88 | +0,05 % | BERENBERG stuft SANOFI auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Sanofi mit einem Kursziel von 105 Euro auf "Buy" belassen. Die Zurückhaltung der Anleger vor der Strategievorstellung des neuen Chefs bremse... ► Artikel lesen | |
| GSK | 22,470 | -0,71 % | BARCLAYS stuft GSK auf 'Underweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für GSK mit einem Kursziel von 1900 Pence auf "Underweight" belassen. Jüngste Absatzdaten belegten auf Wochensicht... ► Artikel lesen | |
| SCHOTT PHARMA | 12,960 | -1,97 % | SCHOTT PHARMA AG & CO KGAA im strukturellen Gleichgewicht | ||
| ELI LILLY | 782,30 | -0,29 % | Stammzelltherapien erreichen den Markt - Mesoblast neben Eli Lilly und Novartis im Fokus | ||
| DERMAPHARM | 40,900 | -0,73 % | Ihre wichtigsten Termine: Nvidia, Qualcomm, Audi, Dermapharm, Docusign und Fraport stehen heute im Fokus! | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland: Fraport... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 22,250 | +7,13 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| NOVARTIS | 126,24 | +0,27 % | Key deals this week: Ecolab, Novartis, 3M and more | ||
| ABBVIE | 178,80 | +0,56 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| ASTRAZENECA | 159,15 | +0,19 % | BERENBERG stuft ASTRAZENECA auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Astrazeneca mit einem Kursziel von 17000 Pence auf "Buy" belassen. Die Ziele für den operativen Cashflow des Pharmakonzerns... ► Artikel lesen | |
| MERCK & CO | 98,50 | -0,30 % | Dividendenbekanntmachungen (16.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADEIA INC US00676P1075 0,05 USD 0,0437 EUR ALTAGAS LTD CA0213611001 0,334 CAD 0,2131 EUR AMERICAN INTEGRITY INSURANCE GROUP INC US0269481091 1... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIDDS AB finden Sie auf Wallstreet Online.